Haemospermia in the Real- Life Setting: A New High-Risk Stratification

To (i) identify a novel risk stratification for patients complaining of haemospermia; and, (ii) compare its predictive ability to select high-risk patients by retrospectively validating the EAU guidelines classification.Data from 283 consecutive patients complaining of a single episode/recurrent haemospermia were retrospectively analyzed. Patients were stratified into low vs high-risk according to EAU guidelines, whose diagnostic performance was then validated. We identified a new risk stratification model based on clinical factors associated with (i) positive semen culture and (ii) prostate cancer (PCa) and bladder cancer (BC). Diagnostic accuracy of the two predictive models (EAU vs New) was assessed and decision curve analyses (DCA) tested their clinical benefit.Overall, 259 (91.5%) were high-risk and 24 (8.5%) low risk according to the EAU guidelines. Recurrent haemospermia was reported by 134 (47.4%) patients. 126 (44.5%) had baseline CCI score ≥ 1. At MVA logistic regression analysis, history of recurrent genito - urinary tract infections was identified as a predictor for positive semen culture (OR: 3.39, 95% CI: 1.77 - 6.57, P =.002). Likewise, baseline CCI ≥ 1 was identified as a predictor for PCa and BC (OR: 1.55, 95% CI: 1.17 - 2.04, P =.009). Sensitivity, specificity, and AUC of the EAU guidelines were 13.3%, 89.2% and 51% respectively, whereas the new model performed substantially better: 98.9%, 58% and 78% respectively.The application of the EAU guidelines risk stratification does not ensure proper identification of high-risk patients complaining of haemospermia. We propose a novel, better performing and easily implementable risk stratification tool.

Authors
Pozzi Edoardo1, 2, 3, 4 , Ventimiglia Eugenio1, 2, 3 , Fallara Giuseppe1, 2, 3, 4 , Capogrosso Paolo 5, 6 , Belladelli Federico1, 2, 3, 4 , Candela Luigi1, 2, 3, 4 , Raffo Massimiliano1, 2, 3, 4 , Costa Antonio1, 2, 3, 4 , Cignoli Daniele1, 2, 3, 4 , Corsini Christian1, 2, 3, 4 , Cazzaniga Walter1, 2, 3, 4 , Boeri Luca7 , Matloob Rayan1, 2, 3 , Capitanio Umberto1, 2, 3 , Montorsi Francesco 1, 2, 3, 4 , Salonia Andrea 1, 2, 3, 4
Journal
Publisher
Elsevier Inc.
Language
English
Pages
146-151
Status
Published
Volume
171
Year
2023
Organizations
  • 1 Division of Experimental Oncology/Unit of Urology
  • 2 IRCCS Ospedale San Raffaele, Milan, Italy
  • 3 URI
  • 4 University Vita-Salute San Raffaele, Milan, Italy
  • 5 Circolo & Fondazione Macchi Hospital – ASST Sette Laghi, Varese, Italy
  • 6 Department of Urology
  • 7 Department of Urology, Foundation IRCCS Ca’ Granda – Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
Share

Other records

Ma T.M., Ballas L.K., Wilhalme Holly, Sachdeva Ankush, Chong Natalie, Sharma Sahil, Yang Tiffany, Basehart Vincent, Reiter R.E., Saigal Christopher, Chamie Karim, Litwin M.S., Rettig M.B., Nickols N.G., Yoon S.M., Smith Lauren, Gao Yu, Steinberg M.L., Cao Minsong, Kishan A.U.
International Journal of Radiation Oncology. Biology. Physics. Elsevier Science Publishing Company, Inc.. Vol. 115. 2023. P. 142-152